Ascorbic Acid Stabilization of Radiopharmaceutical Compositions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Radiopharmaceutical compositions face challenges in stability due to radiolytic decomposition, particularly with short-half-life isotopes like Rubidium-82, Carbon-11, and Nitrogen-13, which decay rapidly, leading to reduced targeting potential and increased toxicity, and existing antioxidants like ascorbic acid are less effective when used in typical biological pH ranges.
Innovation Solution
The use of ascorbic acid as a stabilizer in a specific pH range of 3.5 to 6.0, preferably 4.0 to 5.5, in radiopharmaceutical compositions to enhance stability and shelf-life, while minimizing localized reactions upon injection, by forming a radiopharmaceutical composition with radiopharmaceutical compounds such as 2-tert-Butyl-4-chloro-5-[4-(2-[18F]fluoro-ethoxymethyl)-benzyloxy]-2H-pyridazin-3-one, and incorporating greater than 0.25M ascorbic acid.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ascorbic acid is used as a stabilizer in typical biological pH ranges (6-8), then the radiopharmaceutical composition can be administered to humans with minimal localized reactions, but the antioxidant capacity and stability of the composition is reduced
Solution Approach 1:
The patent changes the pH parameter from the conventional biological range (6-8) to an acidic range (3.5-6.0, preferably 4.0-5.5). This parameter change enhances the antioxidant capacity of ascorbic acid and stabilizes the radiopharmaceutical composition against radiolytic decomposition while maintaining suitability for human administration.
2Productivity
If short-half-life isotopes (Carbon-11, Nitrogen-13) are used in radiopharmaceuticals, then the targeting potential and diagnostic value are improved, but the composition decomposes rapidly due to radiolytic decomposition
Solution Approach 1:
The patent converts the harmful radiolytic decomposition into a manageable challenge by using ascorbic acid as a radical scavenger. The high specific activity and rapid decay of short-half-life isotopes generate free radicals that would normally destroy the radiopharmaceutical, but ascorbic acid scavenges these radicals, transforming the harmful radiolytic environment into a stable formulation that maintains integrity throughout the brief but critical administration window.
3Reliability
If the pH of the radiopharmaceutical composition is lowered to enhance ascorbic acid stability, then the antioxidant capacity increases, but the composition may cause severe localized reactions upon injection
Solution Approach 1:
The patent uses partial buffering with ascorbic acid rather than complete neutralization. The pH is adjusted to 3.5-6.0 (preferably 4.0-5.5), which is partially acidic rather than fully neutral. This partial buffering approach provides sufficient antioxidant capacity to stabilize the radiopharmaceutical while maintaining pH levels that do not cause severe localized reactions upon injection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the antioxidant capacity and stability of radiopharmaceutical compositions, maintaining high radiochemical purity and extending the shelf-life, while ensuring the composition is suitable for human administration without severe localized reactions.
Implementation Method 1
Radical scavengers are often employed as a stabilizer to minimize radiolysis of the radiolabeled molecules. Some stabilizers are 'radical scavenging antioxidants' that readily react with hydroxyl and superoxide radicals.
Implementation Method 2
Radiolysis is caused by the formation of free radicals such as hydroxyl and superoxide radicals. This can propagate via radical reaction and seriously diminish the quality of the composition.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, wherein the pH of said composition is within the range of about 3.5 - 5.5.